
Helix Nanotechnologies
Helix Nanotechnologies is a YC Winter 2017 (W17) company. Based in Boston, MA, USA; Cambridge, MA, USA. Team of 22.
About Helix Nanotechnologies
Summary
Helix Nanotechnologies builds an mRNA platform designed to accelerate the development of treatments for cancer, infectious disease, and environmental challenges. The platform compresses experiments that previously took months or years into weeks, at a fraction of the cost, replacing slow, capital-intensive development cycles with rapid, first-principles mRNA engineering. Current programs include a COVID-19 vaccine candidate targeting immunocompromised patients and an environmental intervention.
From the Y Combinator listing
Next-generation mRNA platform to solve cancer, COVID and climate.
Technology finds information and delivers physical products to us almost instantly. mRNA does the same for biology. At HelixNano, we see a world where treatments are cheap, progress is decentralized, and you can modify biology at the push of a button. By focusing on mRNA improvements from first principles, we’re getting there faster than we thought. Experiments that used to take months or years can be done in weeks and cost thousands instead of millions. The rate limiting step for our progress is now scientific curiosity. Rigid hierarchies and top-down decisions will miss the magic. Some of our most powerful technologies started out as side projects of junior team members. At HelixNano, every individual scientist can have a massive impact on the company's direction. And the more diverse our team, the faster we’ll find the really cool ideas. We've started rolling out some of our new tech — moving a COVID-19 vaccine candidate for the immunocompromised towards the clinic, and testing an intervention with massive environmental impact. But we’re scientists at heart, and team focus is solidly on the horizon.
Facts
- Healthcare / Healthcare -> Drug Discovery and Delivery
- Boston, MA, USA; Cambridge, MA, USA
- 22
- Active
- Growth
Founders (1)
- Nikolai Eroshenko
Score every batch against your own thesis
GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.
How Accelerator intelligence works